EcoDrugPlus

Adenosine A1 Receptor

Ensembl ID : ENSOKIG00005002089
Gene Symbol: ADORA1
3 Cross references
187 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSOKIG00005029728
Gene Symbol: ADORA1
3 Cross references
198 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSOKIG00005010093
Gene Symbol: ADORA1
3 Cross references
147 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSOKIG00005043417
Gene Symbol: ADORA1
3 Cross references
149 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSOKIG00005050839
Gene Symbol: ADORA2A
3 Cross references
190 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSOKIG00005025250
Gene Symbol: ADORA2A
3 Cross references
193 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSOKIG00005042420
Gene Symbol: ADORA2A
3 Cross references
184 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSOKIG00005024897
Gene Symbol: ADORA2B
3 Cross references
192 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSOKIG00005005688
Gene Symbol: ADORA3
3 Cross references
134 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSOKIG00005000573
Gene Symbol: ADORA3
3 Cross references
133 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSOKIG00005040663
Gene Symbol: ADA
3 Cross references
210 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSOKIG00005014057
Gene Symbol: LOC109869233
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).